Abstract
Semaglutide belongs to a class of medications known as glucagon‐like peptide‐1 (GLP‐1) receptor agonists. It mimics the GLP‐1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP‐1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP‐1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
